Table of Contents
<< Previous Issue | Mar 2016 (Vol: 2016, Issue: 3) | Next Issue >> |
- Section: Licensing
-
Baxter’s Foray Into CAR-T Cell Therapy With a Deal Worth US$ 1.7 B
-
AbbVie adds Boehringer Ingelheim’s BI 655066 to its Autoimmune Portfolio
-
Exelixis Partners its Oncology Drug Cabozantinib with Ipsen for US$200 M Upfront
- Section: Mergers & Acquisitions
-
Acorda Boosts Parkinson’s Disease Franchise with US$363 M Acquisition of Biotie
- Section: Opinion & Analysis
-
IMS PharmaDeals Review of 2015